[ad_1]
AstraZeneca Pharma India on Monday stated it has acquired approval from the Medication Controller Normal of India to import coronary heart failure therapy drug Dapagliflozin tablets. The corporate has acquired permission from the DCGI to import pharmaceutical formulations of a brand new drug on the market, the drug agency stated in a regulatory submitting.
Dapagliflozin tablets are indicated for the therapy of coronary heart failure in adults, it added.
The receipt of this permission paves the way in which for the launch of the product in India for the desired indication, topic to the receipt of associated statutory approvals and licenses, it stated.
Shares of the corporate on Monday ended 0.86 per cent down at Rs 3,769.40 apiece on the BSE.
[ad_2]
Source link
